New Antimicrobial Agents for Children / 소아감염
Korean Journal of Pediatric Infectious Diseases
;
: 6-12, 2009.
Artículo
en Coreano
| WPRIM
| ID: wpr-107575
ABSTRACT
There are relatively few novel antimicrobial agents despite the dramatic increase in antimicrobial resistance and multiple drug resistance of clinical isolates worldwide. Vancomycin is still the most widely used antibiotic for treating resistant Gram-positive coccal infections in children, especially for methicillin-resistant Staphylococcus aureus. For children with Gram-positive coccal infections where vancomycin is not effective or older therapeutic agents cannot be tolerated, linezolid, quinupristin-dalfopristin or daptomycin may be useful in the appropriate clinical setting. For Gram-negative infections, new carbapenems await clinical application. Tebipenem pivoxil is a novel oral carbapenem undergoing clinical trials for acute otitis media in pediatric patients. Antiviral drug development is now progressing at the pace of antibiotic development 30 years ago. Newer antiviral agents used for the treatment of herpes viruses and hepatitis C virus infections in children are included in this review.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antivirales
/
Otitis Media
/
Vancomicina
/
Carbapenémicos
/
Virginiamicina
/
Daptomicina
/
Hepacivirus
/
Resistencia a Múltiples Medicamentos
/
Oxazolidinonas
/
Staphylococcus aureus Resistente a Meticilina
Límite:
Niño
/
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Pediatric Infectious Diseases
Año:
2009
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS